These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 24142299

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.
    Antivir Ther; 2013; 18(6):745-54. PubMed ID: 23558061
    [Abstract] [Full Text] [Related]

  • 4. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial.
    Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, ECHO study group.
    Lancet; 2011 Jul 16; 378(9787):238-46. PubMed ID: 21763936
    [Abstract] [Full Text] [Related]

  • 5. Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.
    Allavena C, Dailly E, Reliquet V, Bonnet B, Pineau S, André-Garnier E, Boutoille D, Bouquié R, Raveleau A, Bouchez S, Billaud E, Raffi F.
    J Antimicrob Chemother; 2014 Oct 16; 69(10):2804-8. PubMed ID: 24907142
    [Abstract] [Full Text] [Related]

  • 6. Switching to emtricitabine, tenofovir and rilpivirine as single tablet regimen in virologically suppressed HIV-1-infected patients: a cohort study.
    Gantner P, Reinhart S, Partisani M, Baldeyrou M, Batard ML, Bernard-Henry C, Cheneau C, de Mautort E, Priester M, Fafi-Kremer S, Muret P, Rey D.
    HIV Med; 2015 Feb 16; 16(2):132-6. PubMed ID: 25124291
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM.
    Antivir Ther; 2013 Feb 16; 18(1):105-13. PubMed ID: 23043067
    [Abstract] [Full Text] [Related]

  • 9. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a guide to its use in HIV-1 infection.
    Lyseng-Williamson KA, Scott LJ.
    Clin Drug Investig; 2012 Oct 01; 32(10):715-22. PubMed ID: 22921088
    [Abstract] [Full Text] [Related]

  • 10. Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.
    Nelson MR, Elion RA, Cohen CJ, Mills A, Hodder SL, Segal-Maurer S, Bloch M, Garner W, Guyer B, Williams S, Chuck S, Vanveggel S, Deckx H, Stevens M.
    HIV Clin Trials; 2013 Oct 01; 14(3):81-91. PubMed ID: 23835510
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of emtricitabine, tenofovir, and GS-9137 following coadministration of emtricitabine/tenofovir disoproxil fumarate and ritonavir-boosted GS-9137.
    Ramanathan S, Shen G, Cheng A, Kearney BP.
    J Acquir Immune Defic Syndr; 2007 Jul 01; 45(3):274-9. PubMed ID: 17414929
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients.
    Valantin MA, Bittar R, de Truchis P, Bollens D, Slama L, Giral P, Bonnefont-Rousselot D, Pétour P, Aubron-Olivier C, Costagliola D, Katlama C, TOTEM trial group.
    J Antimicrob Chemother; 2010 Mar 01; 65(3):556-61. PubMed ID: 20053692
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bioequivalence of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen.
    Mathias AA, Hinkle J, Menning M, Hui J, Kaul S, Kearney BP, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen Development Team.
    J Acquir Immune Defic Syndr; 2007 Oct 01; 46(2):167-73. PubMed ID: 17667331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.